Telavancin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Trial Timeline
Jul 1, 2015 → Mar 1, 2016
NCT ID
NCT02392208About Telavancin
Telavancin is a approved stage product being developed by Theravance Biopharma for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02392208. Target conditions include End-Stage Renal Disease, Stage 5 Chronic Kidney Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02753855 | Phase 1 | Completed |
| NCT02392208 | Approved | Completed |
| NCT01321879 | Phase 2 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease